{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:22:18Z","timestamp":1790767338238,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T00:00:00Z","timestamp":1442793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Interdisciplinary Center for Clinical Research (IZKF) Wuerzburg, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carfilzomib, the second\u2010generation proteasome inhibitor, is still awaiting approval for the treatment of multiple myeloma in Europe. Results from clinical trials have demonstrated favorable efficacy in advanced disease but have opened an ongoing debate on cardiac complications related to carfilzomib treatment. \u2018Real\u2010life\u2019 data are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/Patients<\/jats:title>\n                    <jats:p>At our institution, 22 patients were registered within the European Carfilzomib Access Program for treatment with carfilzomib, dexamethasone, and a third combination partner depending on patient characteristics and prior treatment. Patients had received a median of six previous lines of therapy, and most were refractory to bortezomib (77%) and immunomodulatory drugs (95%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall response rate was 65% with a median progression\u2010free survival of 6.0 months and a median duration of response of 6.8 months. Median overall survival was 14.9 months. Grade 3\/4 adverse events (AEs) occurred in 50% of patients with 23% experiencing left ventricular failure. The risk of cardiac AEs was markedly increased after previous radiotherapy of the thoracic spine and concomitant administration of doxorubicin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Carfilzomib\u2010based treatment is efficient in advanced multiple myeloma. In our \u2018real\u2010life\u2019 patients, we found considerable cardiotoxic effects in some cases, indicating a need for careful patient selection and close monitoring of the at\u2010risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.12677","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T16:37:11Z","timestamp":1441211831000},"page":"25-32","source":"Crossref","is-referenced-by-count":72,"title":["\u2018Real\u2010life\u2019 experience of preapproval carfilzomib\u2010based therapy in myeloma \u2013 analysis of cardiac toxicity and predisposing factors"],"prefix":"10.1111","volume":"97","author":[{"given":"Sophia","family":"Danhof","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Strifler","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Department of Internal Medicine Wuerzburg University Medical Center Wuerzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.027"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90739-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568915"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10403"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdu438.29","article-title":"Carfilzomib (K) vs low\u2010dose Corticosteroids and optional Cyclophosphamide in Patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM): results from a Phase 3 Study (FOCUS)","volume":"25","author":"Ludwig H","year":"2014","journal-title":"Ann Oncol"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192506"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1215"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1981.00340060066015"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06659.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00039"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8125"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","unstructured":"KistlerKD RajangamK FaichG LanesS.Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. ASH2012; abstract 2916.","DOI":"10.1182\/blood.V120.21.2916.2916"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5726"},{"key":"e_1_2_6_32_1","unstructured":"Amgen.Phase 3 Head\u2010to\u2010Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis\u00ae(carfilzomib) Over Velcade\u00ae(bortezomib) In Patients With Relapsed Multiple Myeloma. press release 2015."},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563759"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3522"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.27"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103135"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112482"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090690"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12039"},{"key":"e_1_2_6_41_1","doi-asserted-by":"crossref","unstructured":"LaubachJPQuantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). ASH abstract 2013.","DOI":"10.1182\/blood.V122.21.3187.3187"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-915"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000683"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1238"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.2174\/157340311799960645"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602105200"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft034"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.08.071"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1412"},{"key":"e_1_2_6_51_1","article-title":"Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR","volume":"33","author":"Dimopoulos MA","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12677","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:15:12Z","timestamp":1696248912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/ejh.12677"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12677","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725765970.793522189","asserted-by":"object"}]},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]}}}